Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PRT2527

Small molecule · Inhibitor of cyclin-dependent kinase 9 (CDK9) · developed by Prelude Therapeutics

Phase 1 Most advanced trial (none active)
PRLD Developer
1 Registered trials

What is PRT2527?

PRT2527 is a selective inhibitor of CDK9, the catalytic subunit of the P-TEFb elongation factor. It binds CDK9 and blocks its kinase activity, preventing phosphorylation of RNA polymerase II and transcription of anti-apoptotic proteins and oncogenic transcription factors such as MYC. It is being studied in B-cell lymphomas, chronic lymphocytic leukemia, T-cell lymphoma, and myeloid malignancies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
cyclin-dependent kinase 9 (CDK9)
Mechanism
Inhibitor of cyclin-dependent kinase 9 (CDK9)
Pathways
RNA polymerase II transcription elongation, MYC transcription, anti-apoptotic protein expression
Therapy area
Oncology
Developer
Prelude Therapeutics Incorporated (PRLD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05665530 Phase 1 Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) Completed PRLD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid Leukemia (AML)Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Chronic Myelomonocytic Leukemia (CMML)Diffuse Large B-cell Lymphoma (DLBCL)Mantle Cell Lymphoma (MCL)Marginal Zone LymphomaMDS/Myeloproliferative Neoplasm (MPN) Overlap SyndromeMyelodysplastic Syndrome (MDS)Myeloid MalignanciesRichter's SyndromeT-cell Lymphoma

Other drugs acting on CDK9

More from Prelude Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PRLD page.

Follow PRLD, the company behind PRT2527

See PRLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRLD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.